AB0688 Treatment with Rituximab in Systemic Sclerosis Patients: Our Experience in a Pilot Clinical Trial
| Autor: | Clodoveo Ferri, Michele Colaci, Valentina Cestelli, Federica Lumetti, Giulia Cassone, Dilia Giuggioli |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
CD20
medicine.medical_specialty biology business.industry Immunology Microangiopathy Disease medicine.disease Gastroenterology General Biochemistry Genetics and Molecular Biology Surgery Clinical trial Rheumatology Methylprednisolone Fibrosis Vasoactive Internal medicine biology.protein Immunology and Allergy Medicine Rituximab business medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases. 74:1128.1-1128 |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2015-eular.4011 |
| Popis: | Background Systemic sclerosis (SSc) is an immune-mediated disorder characterized by abnormal fibrosis and diffuse microangiopathy with skin and internal organ involvement due to both T- and B-lymphocyte activation. The present study aimed to assess the efficacy of long-term treatment with rituximab (RTX), a chimeric monoclonal antibody that targets B-cell CD20. The rationale for the use of RTX in SSc is based on experimental data suggesting a key role for B cells in regulating the fibrotic process. Objectives The present study aimed to assess the efficacy of long-term treatment with rituximab (RTX) in systemic sclerosis patients. Methods Eleven SSc patients (M/F 3/8, mean age 43.2±10.5SD years, mean disease duration 3.6±6.2SD years) underwent to RTX cycle (weekly infusion of RTX 375 mg/m 2 of body surface plus 100 mg methylprednisolone for 4 weeks); in 10/11 RTX was repeated every 6 months for a total of 2-6 cycles. Patients9 clinical-serological evaluation, including HAQ assessment and visual analogical scale (VAS), was performed every six months. Results At the end of the follow-up period (3.7±2.8 SD years) an improvement of the skin sclerosis involvement was constantly observed; in particular, patients with diffuse SSc cutaneous variant showed a significant decrease of modified Rodnan skin score (from 25±4.1 to 17.2±4.1; p Conclusions Our results indicate that treatment of SSc patients with RTX may be particularly effective for severe skin sclerosis, as suggested by other preliminary trials. The scarce efficacy of RTX on some disease manifestations may suggest the use of combined treatment, namely RTX with other antifibrotic/vasoactive drugs. Disclosure of Interest None declared |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|